Skip to content

NYSE · CIK 0001066764

BESS Bimergen Energy Corp

Insider trading from SEC Form 4. Last filing May 4, 2026.

Bimergen Energy Corp (BESS) has 12 SEC Form 4 filings on file from 6 insiders, the latest filed on May 4, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company

Signals

Open-market buys and sells at Bimergen Energy Corp, scored.

No scored open-market trades yet. Grants, exercises and other rows are below.

Transactions

Every row filed, 16 in all.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Apr 30, 2026Robert J Brilon
Co CEO and CFO
AGrant or award
Options (Right to Buy)derivative
+100,000$0.00$0510,002May 4, 2026
Apr 30, 2026Montgomery L Bannerman
director
AGrant or award
Options (Right to Buy)derivative
+25,000$0.00$070,000May 4, 2026
Apr 30, 2026Benjamin B Tran
Chief Executive Officer
AGrant or award
Options (Right to Buy)derivative
+50,000$0.00$0192,857May 4, 2026
Apr 30, 2026Van H Potter
director
AGrant or award
Options (Right to Buy)derivative
+25,000$0.00$070,000May 4, 2026
Apr 30, 2026Cole Wayne Johnson
Co-CEO and President
AGrant or award
Options (Right to Buy)derivative
+100,000$0.00$0585,715May 4, 2026
Apr 29, 2026James L Stock
director
AGrant or award
Options (Right to Buy)derivative
+25,000$0.00$070,000May 4, 2026
Aug 26, 2025Robert J Brilon
Chief Financial Officer
AGrant or award
Options (Right to Buy)derivative
+210,000$0.00$0210,000Aug 28, 2025
Aug 26, 2025Montgomery L Bannerman
director
AGrant or award
Options (Right to Buy)derivative
+45,000$0.00$045,000Aug 28, 2025
Aug 26, 2025Van H Potter
director
AGrant or award
Options (Right to Buy)derivative
+45,000$0.00$045,000Aug 28, 2025
Aug 26, 2025James L Stock
director
AGrant or award
Options (Right to Buy)derivative
+45,000$0.00$045,000Aug 28, 2025
Apr 24, 2024Cole Wayne Johnson
President
DDisposition to issuer
Options (Right to Buy)derivative
+485,715$0.00$0485,715Aug 28, 2025
Apr 24, 2024Benjamin B Tran
Chief Executive Officer
DDisposition to issuer
Options (Right to Buy)derivative
+142,858$0.00$0142,858Aug 28, 2025
Aug 26, 2025Cole Wayne Johnson
President
AGrant or award
Options (Right to Buy)derivative
+485,715$0.00$0485,715Aug 28, 2025
Aug 26, 2025Benjamin B Tran
Chief Executive Officer
AGrant or award
Options (Right to Buy)derivative
+142,858$0.00$0142,858Aug 28, 2025
May 3, 2024Robert J Brilon
Chief Financial Officer
DDisposition to issuer
Options (Right to Buy)derivative
+71,429$0.00$00Aug 28, 2025
Aug 26, 2025Robert J Brilon
Chief Financial Officer
AGrant or award
Options (Right to Buy)derivative
+71,429$0.00$071,429Aug 28, 2025

Insiders

Everyone who has filed a Form 4 here.

Questions about BESS

Answered from the filings on this page, as of the latest one.

Are insiders buying BESS?

No. In the last 90 days no insider at Bimergen Energy Corp bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade BESS on the open market?

No open-market trade has been scored at Bimergen Energy Corp. The latest Form 4 on file was filed on May 4, 2026 and holds grants, exercises or other rows that are not market trades.

How many insiders file Form 4 at Bimergen Energy Corp?

6 people have filed a Form 4 at Bimergen Energy Corp, among them Robert J Brilon (Co CEO and CFO), Montgomery L Bannerman (director), Cole Wayne Johnson (Co-CEO and President). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.